^
No biomarker
CMML
decitabine/cedazuridine
Sensitive: A1 - Approval
Astex Press Release - 3 weeks
No biomarker
CMML
azacitidine
Sensitive: A1 - Approval
RUNX1 mutation
CMML
venetoclax
Sensitive: C2 – Inclusion Criteria
IDH2 mutation
CMML
venetoclax
Sensitive: C3 – Early Trials
IDH1 mutation
CMML
venetoclax
Sensitive: C3 – Early Trials
NPM1 mutation
CMML
venetoclax
Sensitive: C3 – Early Trials
NRAS mutation
CMML
KB003
Sensitive: C3 – Early Trials
NRAS G12D
CMML
trametinib
Resistant: C4 – Case Studies
RANBP2-ALK fusion
CMML
cytarabine + daunorubicin
Sensitive: C4 – Case Studies
CBL C384Y
CMML
dasatinib
Sensitive: D – Preclinical
KDM6B overexpression + TET2 deletion
CMML
GSKJ4
Sensitive: D – Preclinical
KRAS G12D
CMML
trametinib
Resistant: D – Preclinical
NRAS G12D
CMML
selumetinib
Resistant: D – Preclinical
KRAS G12D
CMML
selumetinib
Resistant: D – Preclinical
CBL mutation
CMML
dasatinib
Sensitive: D – Preclinical